Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-04-20 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于长春百克生物科技股份公司2024年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2024 annual special inspection opinion on the deposit and use of raised funds by Changchun Baike Biotechnology Co., Ltd. It includes extensive financial data on fundraising amounts, usage, interest income, project progress, regulatory compliance, and related board and shareholder meeting decisions. The document references regulatory rules and guidelines related to fundraising and fund management, and it contains substantive financial data and analysis for the fiscal year 2024. It is not a brief announcement or a certification letter but a comprehensive report on the use of raised funds. Therefore, it fits best into the category of Audit Report / Information (AR), as it is a standalone audit and inspection report on the use of funds raised by the company, distinct from a full Annual Report or other categories. FY 2024
2025-04-20 Chinese
长春百克生物科技股份公司董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度履职情况报告" (2024 Annual Performance Report) of the Board Audit Committee of Changchun Baike Biotechnology Co., Ltd. It details the audit committee's activities, meetings, evaluations of external auditors, review of financial reports for 2023 and 2024 quarterly periods, internal audit and control work, and other governance-related matters. The document is a detailed report on the audit committee's duties and performance rather than a standalone audit report or a full annual report. It does not contain full financial statements but focuses on the audit committee's oversight and governance role. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related internal evaluations, excluding full annual reports. The document length is under 5,000 characters, but it is a substantive report, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-20 Chinese
长春百克生物科技股份公司2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024, issued by the company's board and management. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, their identification standards, and remediation status. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a specialized report on internal control effectiveness, which aligns with the category of Audit Report / Information (AR), as it is a standalone audit-related report on internal controls, not a full Annual Report (10-K) or Interim Report (IR). The document length is about 5034 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the best fitting classification is AR with high confidence. FY 2024
2025-04-20 Chinese
长春百克生物科技股份公司第六届董事会第五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Changchun Baike Biotechnology Co., Ltd. It includes approvals of various reports such as the 2024 Annual Report, 2025 Q1 Report, ESG Report, and other internal reports. The document repeatedly states that the full reports are disclosed separately on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full financial reports or substantive financial data but rather summarizes the board's decisions and references the actual reports elsewhere. The document length is 4043 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of board meeting resolutions and related report approvals, not the reports themselves. This fits best under the category of Board/Management Information (MANG), as it announces board meeting decisions and management-related approvals.
2025-04-20 Chinese
长春百克生物科技股份公司2024年度独立董事述职报告（施维）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and committee meetings, key activities, and evaluations during the year 2024. The content focuses on the independent director's duties, attendance, and governance-related activities rather than financial results or audit opinions. It is a report by a board member about their work and governance participation, not an announcement or a proxy statement. This fits the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 4317 characters, which is sufficient for a detailed report but not a full annual report or audit report. There is no indication that this is a certification, regulatory filing, or a report publication announcement. Therefore, the best classification is MANG with high confidence.
2025-04-20 Chinese
长春百克生物科技股份公司2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of Changchun Baike Biotechnology Co., Ltd. It contains detailed financial data for the first quarter of 2025, including income statement figures, balance sheet data, shareholder information, and management discussion on business conditions. The report explicitly states it is unaudited and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2025
2025-04-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.